Hypoxia-targeted triple suicide gene therapy radiosensitizes human colorectal cancer cells

Oncology Reports

Volumn 32, Issue 2, 2014, Pages 723-729

  Hsiao, Hung Tsung ^a,c   Xing, Ligang ^a,b   Deng, Xuelong ^a   Sun, Xiaorong ^a,b   Ling, C Clifton ^a   Li, Gloria C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c E DA HOSPITAL   (Taiwan)

Author keywords

Colon cancer; Cytosine deaminase; Herpes simplex virus 1 thymidine kinase; Hypoxia; Radiation; Uracil phosphoribosyltransferase

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; GANCICLOVIR; THYMIDINE KINASE; URACIL PHOSPHORIBOSYLTRANSFERASE; ANTINEOPLASTIC AGENT; FLUOROURACIL; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CONTROL; CD GENE; CELL HYPOXIA; CELL SURVIVAL; CELL VIABILITY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE INCREASE; FEMALE; GENE EXPRESSION; HSV1 TK GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; SUICIDE GENE THERAPY; TUMOR REGRESSION; UPRT GENE; ANIMAL; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; DRUG SCREENING; EXPERIMENTAL NEOPLASM; GENE THERAPY; NUDE MOUSE; PATHOLOGY; PROCEDURES; SUICIDE TRANSGENE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GANCICLOVIR; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903216444     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3238     Document Type: Article

References (27)

1. Wilson WR and Hay MP: Targeting hypoxia in cancer therapy. Nat Rev Cancer 11: 393-410, 2011.
2. Nordsmark M, Bentzen SM, Rudat V, et al: Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77: 18-24, 2005. (Pubitemid 41503384)
3. Brizel DM, Scully SP, Harrelson JM, et al: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56: 941-943, 1996. (Pubitemid 26065381)
4. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 29: 427-431, 1994.
5. Keith B, Johnson RS and Simon MC: HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12: 9-22, 2012.
6. Wang GL and Semenza GL: General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90: 4304-4308, 1993. (Pubitemid 23134215)
7. Marignol L, Lawler M, Coffey M and Hollywood D: Achieving hypoxia-inducible gene expression in tumors. Cancer Biol Ther 4: 359-364, 2005. (Pubitemid 41351250)
8. Greco O, Marples B, Joiner MC and Scott SD: How to overcome (and exploit)tumor hypoxia for targeted gene therapy. J Cell Physiol 197: 312-325, 2003. (Pubitemid 37487030)
9. Marignol L, Foley R, Southgate TD, Coffey M, Hollywood D and Lawler M: Hypoxia response element-driven cytosine deaminase/5-fluorocytosine gene therapy system: a highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells in vitro. J Gene Med 11: 169-179, 2009.
10. Koshikawa N, Takenaga K, Tagawa M and Sakiyama S: Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res 60: 2936-2941, 2000. (Pubitemid 30395818)
11. Freytag SO, Stricker H, Pegg J, et al: Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63: 7497-7506, 2003. (Pubitemid 37413494)
12. Rogulski KR, Zhang K, Kolozsvary A, Kim JH and Freytag SO: Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res 3: 2081-2088, 1997. (Pubitemid 27505136)
13. Xing L, Sun X, Deng X, et al: Expression of the bifunctional suicide gene CDUPRT increases radiosensitization and bystander effect of 5-FC in prostate cancer cells. Radiother Oncol 92: 345-352, 2009.
14. Porosnicu M, Mian A and Barber GN: The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. Cancer Res 63: 8366-8376, 2003. (Pubitemid 37549491)
15. Sun X, Xing L, Deng X, et al: Hypoxia targeted bifunctional suicide gene expression enhances radiotherapy in vitro and in vivo. Radiother Oncol 105: 57-63, 2012.
16. Xing L, Sun X, Deng X, et al: A triple suicide gene strategy that improves therapeutic effects and incorporates multimodality molecular imaging for monitoring gene functions. Cancer Gene Therapy 20: 358-365, 2013.
17. He F, Deng X, Wen B, et al: Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers. Cancer Res 68: 8597-8606, 2008.
18. Binley K, Askham Z, Martin L, et al: Hypoxia-mediated tumour targeting. Gene Ther 10: 540-549, 2003. (Pubitemid 36432605)
19. Liu J, Harada H, Ogura M, Shibata T and Hiraoka M: Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts. Br J Cancer 96: 1871-1878, 2007. (Pubitemid 46912023)
20. Lee CH, Wu CL and Shiau AL: Hypoxia-induced cytosine deaminase gene expression for cancer therapy. Hum Gene Ther 18: 27-38, 2007. (Pubitemid 46105462)
21. Wang D, Ruan H, Hu L, et al: Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy. Cancer Gene Ther 12: 276-283, 2005. (Pubitemid 40315187)
22. Chen JK, Hu LJ, Wang D, Lamborn KR and Deen DF: Cytosine deaminase/5-fluorocytosine exposure induces bystander and radiosensitization effects in hypoxic glioblastoma cells in vitro. Int J Radiat Oncol Biol Phys 67: 1538-1547, 2007. (Pubitemid 46467180)
23. Freytag SO, Kim JH, Brown SL, Barton K, Lu M and Chung M: Gene therapy strategies to improve the effectiveness of cancer radiotherapy. Expert Opin Biol Ther 4: 1757-1770, 2004. (Pubitemid 39518109)
24. Hwang HS, Davis TW, Houghton JA and Kinsella TJ: Radiosensitivity of thymidylate synthase-deficient human tumor cells is affected by progression through the G1 restriction point into S-phase: implications for fluoropyrimidine radiosensitization. Cancer Res 60: 92-100, 2000. (Pubitemid 30058737)
25. McMasters RA, Saylors RL, Jones KE, Hendrix ME, Moyer MP and Drake RR: Lack of bystander killing in herpes simplex virus thymidine kinase-transduced colon cell lines due to deficient connexin43 gap junction formation. Hum Gen Ther 9: 2253-2261, 1998. (Pubitemid 28498011)
26. Shirakawa T, Gardner TA, Ko SC, et al: Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. J Urol 162: 949-954, 1999. (Pubitemid 29436923)
27. Khatri A, Zhang B, Doherty E, et al: Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice. J Gene Med 8: 1086-1096, 2006. (Pubitemid 44480401)